Takeshi Saito

List of Publications by Year
in descending order

38 papers	2,683 citations	535685 17 h-index	445137 33 g-index
42 all docs	42 docs citations	42 times ranked	3759 citing authors

#	Article	IF	Citations
1	Lipoprotein Z, a hepatotoxic lipoprotein, predicts outcome in alcoholâ€associated hepatitis. Hepatology, 2022, 75, 968-982.	3.6	3
2	Macrophages activated by hepatitis B virus have distinct metabolic profiles and suppress the virus via IL-1Î² to downregulate PPARÎ± and FOXO3. Cell Reports, 2022, 38, 110284.	2.9	16
3	Differential IgG4-Producing Plasma Cell Infiltration in Non- and Post-Transplant Plasma Cell Hepatitis. Transplant International, 2022, 35, 10182.	0.8	1
4	Loss of mitochondrial ATPase ATAD3A contributes to nonalcoholic fatty liver disease through accumulation of lipids and damaged mitochondria. Journal of Biological Chemistry, 2022, 298, 102008.	1.6	9
5	High Prevalence of Chronic Viral Hepatitis and Liver Fibrosis Among Mongols in Southern California. Digestive Diseases and Sciences, 2021, 66, 2833-2839.	1.1	10
6	A Case of Benign Hepatic Cyst with Supra-elevated Cyst Fluid Tumor Markers. Digestive Diseases and Sciences, 2021, 66, 4063-4067.	1.1	0
7	Suppression of hepatitis B virus through therapeutic activation of RIG-I and IRF3 signaling in hepatocytes. IScience, 2021, 24, 101969.	1.9	17
8	Cholesterol-binding translocator protein TSPO regulates steatosis and bile acid synthesis in nonalcoholic fatty liver disease. IScience, 2021, 24, 102457.	1.9	18
9	Infection courses, virological features and IFN-Î± responses of HBV genotypes in cell culture and animal models. Journal of Hepatology, 2021, 75, 1335-1345.	1.8	12
10	Development of Capsular Fibrosis Beneath the Liver Surface in Humans and Mice. Hepatology, 2020, 71, 291-305.	3.6	21
11	Art of Making Artificial Liver: Depicting Human Liver Biology and Diseases in Mice. Seminars in Liver Disease, 2020, 40, 189-212.	1.8	24
12	Special Issue "IFN-Independent ISG Expression and its Role in Antiviral Cell-Intrinsic Innate Immunity". Viruses, 2019, 11, 981.	1.5	7
13	Hepatic IFN-Induced Protein with Tetratricopeptide Repeats Regulation of HCV Infection. Journal of Interferon and Cytokine Research, 2019, 39, 133-146.	0.5	8
14	Regulation of Hepatitis C Virus Infection by Cellular Retinoic Acid Binding Proteins through the Modulation of Lipid Droplet Abundance. Journal of Virology, 2019, 93, .	1.5	20
15	Reply. Gastroenterology, 2017, 153, 328-329.	0.6	0
16	Detection of Occult Hepatitis C Virus Infection in Patients WhoÂAchieved a Sustained Virologic Response to Direct-ActingÂAntiviral Agents for Recurrent InfectionÂAfterÂLiverÂTransplantation. Gastroenterology, 2017, 152, 550-553.e8.	0.6	74
17	Dual modulation of human hepatic zonation via canonical and non-canonical Wnt pathways. Experimental and Molecular Medicine, 2017, 49, e413-e413.	3.2	51
18	Hepatic angiosarcoma with clinical and histological features of Kasabach-Merritt syndrome. World Journal of Gastroenterology, 2017, 23, 2443.	1.4	15

#	Article	IF	Citations
19	Retinoid regulation of antiviral innate immunity in hepatocytes. Hepatology, 2016, 63, 1783-1795.	3.6	23
20	Organ system view of the hepatic innate immunity in HCV infection. Journal of Medical Virology, 2016, 88, 2025-2037.	2.5	12
21	Comparison of Demographic and Clinical Characteristics of Hispanic and Asian Chronic Hepatitis B Patients in Southern California. Journal of Clinical Gastroenterology, 2016, 50, 602-607.	1.1	2
22	An Internally Translated MAVS Variant Exposes Its Amino-terminal TRAF-Binding Motifs to Deregulate Interferon Induction. PLoS Pathogens, 2015, 11, e1005060.	2.1	12
23	Novel antiviral host factor, TNK1, regulates IFN signaling through serine phosphorylation of STAT1. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 1909-1914.	3.3	34
24	Innate Immune Tolerance and the Role of Kupffer Cells in Differential Responses to Interferon Therapy Among Patients With HCV Genotype 1 Infection. Gastroenterology, 2013, 144, 402-413.e12.	0.6	66
25	Isolated arterioportal fistula presenting with variceal hemorrhage. World Journal of Gastroenterology, 2013, 19, 2714.	1.4	5
26	RNase L releases a small RNA from HCV RNA that refolds into a potent PAMP. Rna, 2010, 16, 2108-2119.	1.6	117
27	PS2-75 Regulation of the response to interferon therapy through innate immune tolerance during hepatitis C virus infection. Cytokine, 2010, 52, 66.	1.4	0
28	Role of small RNAS generated by RNASE L in signaling innate immunity against hepatitis C virus. Cytokine, 2009, 48, 37.	1.4	0
29	Regulation of innate immunity against hepatitis C virus infection. Hepatology Research, 2008, 38, 115-122.	1.8	46
30	Innate immunity induced by composition-dependent RIG-I recognition of hepatitis C virus RNA. Nature, 2008, 454, 523-527.	13.7	646
31	Differential recognition of double-stranded RNA by RIG-Iâ€“like receptors in antiviral immunity. Journal of Experimental Medicine, 2008, 205, 1523-1527.	4.2	129
32	290 Defining the pathogen associated molecular patterns (PAMPs) of RNA viruses and their recognition by RIG-I to mediated innate immune defenses. Cytokine, 2008, 43, 312.	1.4	0
33	Regulation of innate antiviral defenses through a shared repressor domain in RIG-I and LGP2. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 582-587.	3.3	667
34	Principles of intracellular viral recognition. Current Opinion in Immunology, 2007, 19, 17-23.	2.4	136
35	Translational enhancement of HCV RNA genotype 1b by 3â€²-untranslated and envelope 2 protein-coding sequences. Virology, 2006, 345, 404-415.	1.1	3
36	Viral and therapeutic control of IFN-beta promoter stimulator 1 during hepatitis C virus infection. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 6001-6006.	3.3	394

#	Article	IF	Citations
37	Sequence Analysis of Pephd Within Hcv E2 Region and Correlation With Resistance of Interferon Therapy in Japanese Patients Infected With Hcv Genotypes 2A and 2B. American Journal of Gastroenterology, 2003, 98, 1377-1383.	0.2	29
38	A case of autoimmune pancreatitis responding to steroid therapy. Pancreatology, 2002, 2, 550-556.	0.5	52